Variant allelic frequencies of driver mutations can identify gliomas with potentially false-negative MGMT promoter methylation results

MGMT promoter methylation testing is required for prognosis and predicting temozolomide response in gliomas. Accurate results depend on sufficient tumor cellularity, but histologic estimates of cellularity are subjective. We sought to determine whether driver mutation variant allelic frequency (VAF)...

Descripción completa

Detalles Bibliográficos
Autores principales: McCord, Matthew, Jamshidi, Pouya, Thirunavu, Vineeth, Santana-Santos, Lucas, Vormittag-Nocito, Erica, Dittman, David, Parker, Stephanie, Baczkowski, Joseph, Jennings, Lawrence, Walshon, Jordain, McCortney, Kathleen, Galbraith, Kristyn, Zhang, Hui, Lukas, Rimas V., Stupp, Roger, Dixit, Karan, Kumthekar, Priya, Heimberger, Amy B., Snuderl, Matija, Horbinski, Craig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623846/
https://www.ncbi.nlm.nih.gov/pubmed/37919784
http://dx.doi.org/10.1186/s40478-023-01680-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623846/
https://www.ncbi.nlm.nih.gov/pubmed/37919784
http://dx.doi.org/10.1186/s40478-023-01680-0

Ejemplares similares